PL3959213T3 - Pirymidynowe inhibitory JAK w leczeniu chorób skóry - Google Patents

Pirymidynowe inhibitory JAK w leczeniu chorób skóry

Info

Publication number
PL3959213T3
PL3959213T3 PL20727424.2T PL20727424T PL3959213T3 PL 3959213 T3 PL3959213 T3 PL 3959213T3 PL 20727424 T PL20727424 T PL 20727424T PL 3959213 T3 PL3959213 T3 PL 3959213T3
Authority
PL
Poland
Prior art keywords
pyrimidine
treatment
skin diseases
jak inhibitors
jak
Prior art date
Application number
PL20727424.2T
Other languages
English (en)
Inventor
Philip A. GERKEN
Jianhua Chao
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of PL3959213T3 publication Critical patent/PL3959213T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20727424.2T 2019-04-24 2020-04-23 Pirymidynowe inhibitory JAK w leczeniu chorób skóry PL3959213T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837827P 2019-04-24 2019-04-24
PCT/US2020/029466 WO2020219640A1 (en) 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases

Publications (1)

Publication Number Publication Date
PL3959213T3 true PL3959213T3 (pl) 2024-11-04

Family

ID=70779856

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20727424.2T PL3959213T3 (pl) 2019-04-24 2020-04-23 Pirymidynowe inhibitory JAK w leczeniu chorób skóry

Country Status (11)

Country Link
US (1) US11439641B2 (pl)
EP (1) EP3959213B1 (pl)
JP (1) JP7482152B2 (pl)
AR (1) AR118767A1 (pl)
CA (1) CA3135388A1 (pl)
ES (1) ES2994097T3 (pl)
HR (1) HRP20241053T1 (pl)
HU (1) HUE067909T2 (pl)
PL (1) PL3959213T3 (pl)
TW (1) TW202106681A (pl)
WO (1) WO2020219640A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
MX2021006283A (es) * 2018-11-30 2021-10-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
HUE066802T2 (hu) * 2019-04-24 2024-09-28 Theravance Biopharma R&D Ip Llc JAK kináz inhibitor észter és karbonát pirimidin vegyületek
CN116390922B (zh) * 2020-10-21 2025-07-18 珠海联邦制药股份有限公司 硒杂环类化合物及其应用
WO2022094174A1 (en) * 2020-10-30 2022-05-05 Children's Hospital Medical Center Compositions and methods for the treatment of esophageal conditions
EP4696710A3 (en) * 2021-05-03 2026-05-06 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN117500504A (zh) * 2021-05-03 2024-02-02 因赛特公司 用于治疗结节性痒疹的鲁索替尼
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
EP1345925B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20070179125A1 (en) 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
MX2008016523A (es) 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (pl) 2014-08-21 2018-03-31
KR20180011272A (ko) 2015-05-28 2018-01-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나제 저해제로서 나프티리딘 화합물
TWI726094B (zh) 2016-04-28 2021-05-01 美商施萬生物製藥研發Ip有限責任公司 作為jak激酶抑制劑之嘧啶化合物
CN106588885B (zh) 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2019084383A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
CN111601804B (zh) 2018-11-27 2024-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
MX2021006283A (es) 2018-11-30 2021-10-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
HUE066802T2 (hu) * 2019-04-24 2024-09-28 Theravance Biopharma R&D Ip Llc JAK kináz inhibitor észter és karbonát pirimidin vegyületek
CN113372364B (zh) 2020-03-10 2024-05-31 明慧医药(上海)有限公司 一类jak激酶抑制剂及其制备和应用
CN113372351A (zh) 2020-03-10 2021-09-10 明慧医药(杭州)有限公司 一类jak激酶抑制剂及其制备和应用

Also Published As

Publication number Publication date
HUE067909T2 (hu) 2024-11-28
WO2020219640A1 (en) 2020-10-29
JP2022529371A (ja) 2022-06-21
JP7482152B2 (ja) 2024-05-13
EP3959213C0 (en) 2024-06-05
HRP20241053T1 (hr) 2024-11-08
AR118767A1 (es) 2021-10-27
CA3135388A1 (en) 2020-10-29
US20200338073A1 (en) 2020-10-29
US11439641B2 (en) 2022-09-13
EP3959213B1 (en) 2024-06-05
EP3959213A1 (en) 2022-03-02
ES2994097T3 (en) 2025-01-17
TW202106681A (zh) 2021-02-16

Similar Documents

Publication Publication Date Title
HUE067909T2 (hu) Pirimidin JAK-inhibitorok bõrbetegségek kezelésére
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
IL276383A (en) Treatment of ophthalmological diseases
IL288523A (en) Compounds for the treatment of pd-l1 diseases
IL279260A (en) KDM1A inhibitors for the treatment of diseases
IL291735A (en) Heteroarylbiphenylamines for the treatment of pd-l1 diseases
IL270469B1 (en) Compounds for the prevention and treatment of diseases and their use
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
SG11202006374VA (en) Treatment of demyelinating diseases
IL282643A (en) Soft combinations for the treatment of hematological diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3744347A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES
IL282360A (en) Treatment for neurological diseases
PL3603621T3 (pl) Liposomy do leczenia chorób oczu
IL291146A (en) Treatment of hidradenitis with jak inhibitors
EP3883567B8 (en) Naphthyridinone-aniline compounds for treatment of dermal disorders
ZA202106250B (en) Therapeutic uses of dulaglutide
PL3761982T3 (pl) Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych
PT3833378T (pt) Tratamento de verrugas
CA3266235A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES
GB202015959D0 (en) Treatment of diseases involving NAD
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
EP3755334A4 (en) TREATMENT OF LIVER DISEASES
GB201909438D0 (en) Treatment of diseases
GB2603379B (en) Avocatin B for the treatment of diseases and conditions